Conversation with The Cancer LetterFree Sigal: $75 Million Not Enough for FDA Reform February 12, 2016Vol.42 No.06
Conversation with The Cancer LetterFree Daniel: FDA Does Not Have A Reliable Surveillance System For Medical Devices December 18, 2015Vol.41 No.46By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Pilot: Don’t Change 510(k), Put More Money Into Enforcing FDA Reporting Laws December 18, 2015Vol.41 No.46By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Vodra: 510(k) Does Not Assess Risk; Needs to be Split Into Multiple Risk Groups December 18, 2015Vol.41 No.46
Conversation with The Cancer Letter Lilly’s PACE Continuous Innovation Indicators Visualize Progress and Value in Research October 30, 2015Vol.41 No.40By Matthew Bin Han Ong
Conversation with The Cancer LetterFree Wender: ACS Guideline Hinges on Shared Decision Making October 23, 2015Vol.41 No.39By Paul Goldberg
Conversation with The Cancer LetterFree AstraZeneca Exec Discusses Iressa’s Future in the U.S. August 07, 2015Vol.41 No.31By Paul Goldberg
Conversation with The Cancer LetterFree The War on Cancer (Drug Prices): Political Education of Hagop Kantarjian July 30, 2015Vol.41 No.30By Paul Goldberg
Conversation with The Cancer Letter Doroshow: NCI-MATCH is an Example of What Smart Public-Private Partnerships Can Do June 05, 2015Vol.41 No.22By Paul Goldberg
Conversation with The Cancer LetterFree Fisher Discusses Turnaround at Fox Chase May 15, 2015Vol.41 No.19By Paul Goldberg
